{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T15:33:20Z","timestamp":1790696000679,"version":"4.1.0"},"reference-count":21,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2015,10,31]],"date-time":"2015-10-31T00:00:00Z","timestamp":1446249600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["30973189"],"award-info":[{"award-number":["30973189"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Natural Science Foundation of Liaoning, China","award":["2013021040"],"award-info":[{"award-number":["2013021040"]}]},{"DOI":"10.13039\/501100013286","name":"Research Fund for the Doctoral Program of Higher Education of China","doi-asserted-by":"crossref","award":["20132104110014"],"award-info":[{"award-number":["20132104110014"]}],"id":[{"id":"10.13039\/501100013286","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Med Oncol"],"published-print":{"date-parts":[[2015,12]]},"DOI":"10.1007\/s12032-015-0706-8","type":"journal-article","created":{"date-parts":[[2015,10,31]],"date-time":"2015-10-31T07:58:49Z","timestamp":1446278329000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":40,"title":["Over-expression of Sirt1 contributes to chemoresistance and indicates poor prognosis in serous epithelial ovarian cancer (EOC)"],"prefix":"10.1007","volume":"32","author":[{"given":"Ting","family":"Shuang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Min","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yingying","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cong","family":"Shi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2015,10,31]]},"reference":[{"issue":"12","key":"706_CR1","doi-asserted-by":"crossref","first-page":"2893","DOI":"10.1002\/ijc.25516","volume":"127","author":"J Ferlay","year":"2010","unstructured":"Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer. 2010;127(12):2893\u2013917. doi: 10.1002\/ijc.25516 .","journal-title":"Int J Cancer"},{"issue":"4","key":"706_CR2","doi-asserted-by":"crossref","first-page":"225","DOI":"10.3322\/caac.20006","volume":"59","author":"A Jemal","year":"2009","unstructured":"Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ. Cancer statistics, 2009. CA Cancer J Clin. 2009;59(4):225\u201349. doi: 10.3322\/caac.20006 .","journal-title":"CA Cancer J Clin"},{"issue":"6","key":"706_CR3","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1016\/S0025-6196(11)61196-8","volume":"82","author":"GD Aletti","year":"2007","unstructured":"Aletti GD, Gallenberg MM, Cliby WA, Jatoi A, Hartmann LC. Current management strategies for ovarian cancer. Mayo Clin Proc. 2007;82(6):751\u201370. doi: 10.4065\/82.6.751 .","journal-title":"Mayo Clin Proc"},{"issue":"Suppl 3","key":"706_CR4","doi-asserted-by":"crossref","first-page":"S3","DOI":"10.1038\/sj.bjc.6601494","volume":"89","author":"WP McGuire 3rd","year":"2003","unstructured":"McGuire WP 3rd, Markman M. Primary ovarian cancer chemotherapy: current standards of care. Br J Cancer. 2003;89(Suppl 3):S3\u20138. doi: 10.1038\/sj.bjc.6601494 .","journal-title":"Br J Cancer"},{"issue":"6771","key":"706_CR5","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1038\/35001622","volume":"403","author":"S Imai","year":"2000","unstructured":"Imai S, Armstrong CM, Kaeberlein M, Guarente L. Transcriptional silencing and longevity protein Sir2 is an NAD-dependent histone deacetylase. Nature. 2000;403(6771):795\u2013800. doi: 10.1038\/35001622 .","journal-title":"Nature"},{"issue":"11","key":"706_CR6","doi-asserted-by":"crossref","first-page":"5807","DOI":"10.1073\/pnas.110148297","volume":"97","author":"J Landry","year":"2000","unstructured":"Landry J, Sutton A, Tafrov ST, Heller RC, Stebbins J, Pillus L, et al. The silencing protein SIR2 and its homologs are NAD-dependent protein deacetylases. Proc Natl Acad Sci USA. 2000;97(11):5807\u201311. doi: 10.1073\/pnas.110148297 .","journal-title":"Proc Natl Acad Sci USA"},{"issue":"5487","key":"706_CR7","doi-asserted-by":"crossref","first-page":"2126","DOI":"10.1126\/science.289.5487.2126","volume":"289","author":"SJ Lin","year":"2000","unstructured":"Lin SJ, Defossez PA, Guarente L. Requirement of NAD and SIR2 for life-span extension by calorie restriction in Saccharomyces cerevisiae. Science. 2000;289(5487):2126\u20138.","journal-title":"Science"},{"issue":"7255","key":"706_CR8","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1038\/nature08197","volume":"460","author":"T Finkel","year":"2009","unstructured":"Finkel T, Deng CX, Mostoslavsky R. Recent progress in the biology and physiology of sirtuins. Nature. 2009;460(7255):587\u201391. doi: 10.1038\/nature08197 .","journal-title":"Nature"},{"issue":"4","key":"706_CR9","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1038\/nrn3209","volume":"13","author":"RH Houtkooper","year":"2012","unstructured":"Houtkooper RH, Pirinen E, Auwerx J. Sirtuins as regulators of metabolism and healthspan. Nat Rev Mol Cell Biol. 2012;13(4):225\u201338. doi: 10.1038\/nrm3293 .","journal-title":"Nat Rev Mol Cell Biol"},{"issue":"37","key":"706_CR10","doi-asserted-by":"crossref","first-page":"5489","DOI":"10.1038\/sj.onc.1210616","volume":"26","author":"LR Saunders","year":"2007","unstructured":"Saunders LR, Verdin E. Sirtuins: critical regulators at the crossroads between cancer and aging. Oncogene. 2007;26(37):5489\u2013504. doi: 10.1038\/sj.onc.1210616 .","journal-title":"Oncogene"},{"issue":"4","key":"706_CR11","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1097\/MOH.0b013e328360ab64","volume":"20","author":"W Chen","year":"2013","unstructured":"Chen W, Bhatia R. Roles of SIRT1 in leukemogenesis. Curr Opin Hematol. 2013;20(4):308\u201313. doi: 10.1097\/MOH.0b013e328360ab64 .","journal-title":"Curr Opin Hematol"},{"key":"706_CR12","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1186\/1471-2407-14-604","volume":"14","author":"RS Derr","year":"2014","unstructured":"Derr RS, van Hoesel AQ, Benard A, Goossens-Beumer IJ, Sajet A, Dekker-Ensink NG, et al. High nuclear expression levels of histone-modifying enzymes LSD1, HDAC2 and SIRT1 in tumor cells correlate with decreased survival and increased relapse in breast cancer patients. BMC Cancer. 2014;14:604. doi: 10.1186\/1471-2407-14-604 .","journal-title":"BMC Cancer"},{"issue":"11","key":"706_CR13","first-page":"2357","volume":"6","author":"L Han","year":"2013","unstructured":"Han L, Liang XH, Chen LX, Bao SM, Yan ZQ. SIRT1 is highly expressed in brain metastasis tissues of non-small cell lung cancer (NSCLC) and in positive regulation of NSCLC cell migration. Int J Clin Exp Pathol. 2013;6(11):2357\u201365.","journal-title":"Int J Clin Exp Pathol"},{"issue":"14","key":"706_CR14","doi-asserted-by":"crossref","first-page":"6612","DOI":"10.1158\/0008-5472.CAN-07-0085","volume":"67","author":"DM Huffman","year":"2007","unstructured":"Huffman DM, Grizzle WE, Bamman MM, Kim JS, Eltoum IA, Elgavish A, et al. SIRT1 is significantly elevated in mouse and human prostate cancer. Cancer Res. 2007;67(14):6612\u20138. doi: 10.1158\/0008-5472.CAN-07-0085 .","journal-title":"Cancer Res"},{"issue":"6","key":"706_CR15","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1007\/s12032-014-0965-9","volume":"31","author":"L Lv","year":"2014","unstructured":"Lv L, Shen Z, Zhang J, Zhang H, Dong J, Yan Y, et al. Clinicopathological significance of SIRT1 expression in colorectal adenocarcinoma. Med Oncol. 2014;31(6):965. doi: 10.1007\/s12032-014-0965-9 .","journal-title":"Med Oncol"},{"issue":"3\u20134","key":"706_CR16","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1177\/1947601912473826","volume":"4","author":"Z Wang","year":"2013","unstructured":"Wang Z, Chen W. Emerging roles of SIRT1 in cancer drug resistance. Genes Cancer. 2013;4(3\u20134):82\u201390. doi: 10.1177\/1947601912473826 .","journal-title":"Genes Cancer"},{"key":"706_CR17","doi-asserted-by":"crossref","first-page":"977","DOI":"10.2147\/OTT.S82378","volume":"8","author":"C Li","year":"2015","unstructured":"Li C, Wang L, Zheng L, Zhan X, Xu B, Jiang J, et al. SIRT1 expression is associated with poor prognosis of lung adenocarcinoma. OncoTargets Ther. 2015;8:977\u201384. doi: 10.2147\/OTT.S82378 .","journal-title":"OncoTargets Ther"},{"issue":"6","key":"706_CR18","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1016\/j.prp.2013.03.011","volume":"209","author":"SJ Noh","year":"2013","unstructured":"Noh SJ, Baek HA, Park HS, Jang KY, Moon WS, Kang MJ, et al. Expression of SIRT1 and cortactin is associated with progression of non-small cell lung cancer. Pathol Res Pract. 2013;209(6):365\u201370. doi: 10.1016\/j.prp.2013.03.011 .","journal-title":"Pathol Res Pract"},{"issue":"6","key":"706_CR19","doi-asserted-by":"crossref","first-page":"1553","DOI":"10.1002\/cam4.310","volume":"3","author":"A Noguchi","year":"2014","unstructured":"Noguchi A, Kikuchi K, Zheng H, Takahashi H, Miyagi Y, Aoki I, et al. SIRT1 expression is associated with a poor prognosis, whereas DBC1 is associated with favorable outcomes in gastric cancer. Cancer Med. 2014;3(6):1553\u201361. doi: 10.1002\/cam4.310 .","journal-title":"Cancer Med"},{"issue":"5","key":"706_CR20","doi-asserted-by":"crossref","first-page":"3240","DOI":"10.1007\/s12032-012-0260-6","volume":"29","author":"M Wu","year":"2012","unstructured":"Wu M, Wei W, Xiao X, Guo J, Xie X, Li L, et al. Expression of SIRT1 is associated with lymph node metastasis and poor prognosis in both operable triple-negative and non-triple-negative breast cancer. Med Oncol. 2012;29(5):3240\u20139. doi: 10.1007\/s12032-012-0260-6 .","journal-title":"Med Oncol"},{"issue":"4","key":"706_CR21","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1158\/1535-7163.MCT-12-0700","volume":"12","author":"S Portmann","year":"2013","unstructured":"Portmann S, Fahrner R, Lechleiter A, Keogh A, Overney S, Laemmle A, et al. Antitumor effect of SIRT1 inhibition in human HCC tumor models in vitro and in vivo. Mol Cancer Ther. 2013;12(4):499\u2013508. doi: 10.1158\/1535-7163.MCT-12-0700 .","journal-title":"Mol Cancer Ther"}],"container-title":["Medical Oncology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12032-015-0706-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s12032-015-0706-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12032-015-0706-8","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,5,16]],"date-time":"2020-05-16T01:59:07Z","timestamp":1589594347000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s12032-015-0706-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,10,31]]},"references-count":21,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2015,12]]}},"alternative-id":["706"],"URL":"https:\/\/doi.org\/10.1007\/s12032-015-0706-8","relation":{},"ISSN":["1357-0560","1559-131X"],"issn-type":[{"value":"1357-0560","type":"print"},{"value":"1559-131X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,10,31]]},"article-number":"260"}}